









Markets
/
Stocks
/
nasdaq-sxtp
/

60 Degrees Pharmaceuticals Inc

SXTP

4.160USD

+0.310+8.05%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

4.27MMarket Cap

3.70P/E TTM



60 Degrees Pharmaceuticals Inc

4.160

+0.310+8.05%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of 60 Degrees Pharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

60 Degrees Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 101 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 17.60.In the medium term, the stock price is expected to trend down.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

60 Degrees Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

101 / 159

Overall Ranking

271 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

60 Degrees Pharmaceuticals Inc Highlights

StrengthsRisks

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 33.28% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 681.35K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 681.35K.

Overvalued

The company’s latest PE is 3.70, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 52.23K shares, decreasing 35.34% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 20.00 shares of this stock.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

17.600

Target Price

+357.14%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of 60 Degrees Pharmaceuticals Inc is 7.32, ranking 118 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 528.56K, representing a year-over-year increase of 256.87%, while its net profit experienced a year-over-year increase of 7.38%.

Score

Industry at a Glance

Previous score

7.32

Change



Financials

8.84

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.88

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.03

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.45

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.39

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

60 Degrees Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of 60 Degrees Pharmaceuticals Inc is 6.79, ranking 112 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 3.70, which is 25.00% below the recent high of 4.62 and 177.84% above the recent low of -2.88.

Score

Industry at a Glance

Previous score

6.79

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 101/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of 60 Degrees Pharmaceuticals Inc is 8.00, ranking 57 out of 159 in the Pharmaceuticals industry. The average price target is 4.40, with a high of 6.00 and a low of 2.80.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

17.600

Target Price

+301.83%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

60 Degrees Pharmaceuticals Inc

SXTP

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of 60 Degrees Pharmaceuticals Inc is 6.41, ranking 128 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 8.07 and the support level at 0.81, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.36

Change

0.05

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.076

Buy

RSI(14)

55.318

Neutral

STOCH(KDJ)(9,3,3)

36.715

Neutral

ATR(14)

1.166

High Vlolatility

CCI(14)

-14.589

Neutral

Williams %R

65.976

Sell

TRIX(12,20)

2.493

Sell

StochRSI(14)

54.831

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

4.010

Buy

MA10

4.390

Sell

MA20

3.510

Buy

MA50

3.312

Buy

MA100

3.923

Buy

MA200

2.950

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of 60 Degrees Pharmaceuticals Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 4.06%, representing a quarter-over-quarter decrease of 63.12%. The largest institutional shareholder is The Vanguard, holding a total of 20.00 shares, representing 0.00% of shares outstanding, with 79.75% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Orca Capital GmbH

166.23K

Dow (Geoffrey S)

45.42K

+99.30%

Knight Therapeutics, Inc.

33.90K

+76.26%

DRW Securities, LLC

25.21K

Xu (Cheryl)

15.82K

+79.40%

Geode Capital Management, L.L.C.

12.45K

-0.54%

Miller (Tyrone)

5.27K

Landon (Kristen)

4.54K

Tower Research Capital LLC

3.14K

+20.86%

UBS Switzerland AG

1.48K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of 60 Degrees Pharmaceuticals Inc is 1.77, ranking 145 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.